阿柏西普治疗年龄相关性黄斑变性及息肉状脉络膜血管病变  

Treatment of age-related macular degeneration and polypoidal choroidal vasculopathy by Aflibercept

作　　者：齐敏 孔珺[1] Qi Min;Kong Jun(Department of Ophthalmology,the Fourth Affiliated Hospital of China Medical University,Eye Hospital of China Medical University,the Key Lenticular Laboratory of Liaoning Province,Shenyang 110000,China)

机构地区：[1]中国医科大学附属第四医院眼科,中国医科大学眼科医院,辽宁省晶状体学重点实验室,沈阳110000

出　　处：《国际眼科纵览》2019年第5期355-359,共5页International Review of Ophthalmology

基　　金：辽宁省自然科学基金(201602832);辽宁省光复眼病防治基金(hxkt41)。

摘　　要：阿柏西普是一种完全人源化重组融合蛋白,可通过阻断血管内皮生长因子(vascular endothelial growth factor,VEGF)家庭成员中的VEGF-A的所有亚型及胎盘生长因子(placental growth factor,PLGF)而起到抗新生血管的作用。多项大型临床试验已证实阿柏西普用于治疗年龄相关性黄斑变性(age-related macular degeneration,AMD)和息肉状脉络膜血管病变(polypoidal choroidal vasculpathy,PCV)的疗效及安全性,而且阿柏西普对雷珠单抗耐药的AMD及PCV的治疗也有效。作为一种新的抗VEGF药物,与哌加他尼钠(pegaptanib)、雷珠单抗(ranibizumab)和贝伐单抗(bevacizumab)等抗VEGF药物相比较,阿柏西普作用靶点更广、亲和力更强、作用时间更长,因此可在不降低药物疗效的情况下减少给药频次、降低反复注药带来的不良后果,并且能够减轻患者的经济负担。Aflibercept is a fully humanized recombinant fusion protein that blocks all subtypes of vascular endothelial growth factor(VEGF)-A and placental growth factor(PLGF)in the VEGF family.A number of large clinical trials have confirmed the efficacy and safety of aflibercept in the treatment of age-related macular degeneration(AMD)and polypoidal choroidal vasculopathys(PCV)as well as in the treatment of AMD and PCV which arc resistant to ranibizumab.Compared with other anti-VEGF drugs,such as pegaptanib,ranibizumab and bevacizumab,aflibercept,which is a new generation of anti-VEGF drug,has a wider target,stronger affinity and longer action time.Therefore,it can reduce the frequency of drug administration,the adverse effect caused by the repeated injection,and the economic burden of patients without reducing the curative effects.

关 键 词：阿柏西普 血管内皮生长因子 年龄相关性黄斑变性 息肉状脉络膜血管病变 

分 类 号：R73[医药卫生—肿瘤]